View in EDS

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Authors: Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Albiges L; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France., Tomczak P; Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Voss MH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Chahoud J; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Mochalova A; Department of Chemotherapy, Clinical Hospital Number 1 MEDSI, Moscow, Russia., Procopio G; Department of Medical Oncology, Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy., Mahammedi H; Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France., Zengerling F; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany., Kim C; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Osawa T; Department of Urology, Hokkaido University Hospital, Sapporo, Japan., Angel M; Department of Genitourinary Cancer, Instituto Alexander Fleming, Buenos Aires, Argentina., Gupta S; Genentech, South San Francisco, CA, USA., Khan O; Roche Product, Welwyn Garden City, UK., Bergthold G; F Hoffmann-La Roche, Basel, Switzerland., Liu B; Genentech, South San Francisco, CA, USA., Kalaitzidou M; Roche Product, Welwyn Garden City, UK., Huseni M; Genentech, South San Francisco, CA, USA., Scheffold C; Exelixis, Alameda, CA, USA., Powles T; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
Source: Lancet (London, England) [Lancet] 2023 Jul 15; Vol. 402 (10397), pp. 185-195. Date of Electronic Publication: 2023 Jun 05.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37290461
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pal+SK%22">Pal SK</searchLink>; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Albiges+L%22">Albiges L</searchLink>; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Tomczak+P%22">Tomczak P</searchLink>; Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland.<br /><searchLink fieldCode="AU" term="%22Suárez+C%22">Suárez C</searchLink>; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Voss+MH%22">Voss MH</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22de+Velasco+G%22">de Velasco G</searchLink>; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Chahoud+J%22">Chahoud J</searchLink>; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Mochalova+A%22">Mochalova A</searchLink>; Department of Chemotherapy, Clinical Hospital Number 1 MEDSI, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Procopio+G%22">Procopio G</searchLink>; Department of Medical Oncology, Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Mahammedi+H%22">Mahammedi H</searchLink>; Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France.<br /><searchLink fieldCode="AU" term="%22Zengerling+F%22">Zengerling F</searchLink>; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Kim+C%22">Kim C</searchLink>; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Osawa+T%22">Osawa T</searchLink>; Department of Urology, Hokkaido University Hospital, Sapporo, Japan.<br /><searchLink fieldCode="AU" term="%22Angel+M%22">Angel M</searchLink>; Department of Genitourinary Cancer, Instituto Alexander Fleming, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Gupta+S%22">Gupta S</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Khan+O%22">Khan O</searchLink>; Roche Product, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Bergthold+G%22">Bergthold G</searchLink>; F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Liu+B%22">Liu B</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kalaitzidou+M%22">Kalaitzidou M</searchLink>; Roche Product, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Huseni+M%22">Huseni M</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Exelixis, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2023 Jul 15; Vol. 402 (10397), pp. 185-195. <i>Date of Electronic Publication: </i>2023 Jun 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37290461
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(23)00922-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 185
    Titles:
      – TitleFull: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pal SK
      – PersonEntity:
          Name:
            NameFull: Albiges L
      – PersonEntity:
          Name:
            NameFull: Tomczak P
      – PersonEntity:
          Name:
            NameFull: Suárez C
      – PersonEntity:
          Name:
            NameFull: Voss MH
      – PersonEntity:
          Name:
            NameFull: de Velasco G
      – PersonEntity:
          Name:
            NameFull: Chahoud J
      – PersonEntity:
          Name:
            NameFull: Mochalova A
      – PersonEntity:
          Name:
            NameFull: Procopio G
      – PersonEntity:
          Name:
            NameFull: Mahammedi H
      – PersonEntity:
          Name:
            NameFull: Zengerling F
      – PersonEntity:
          Name:
            NameFull: Kim C
      – PersonEntity:
          Name:
            NameFull: Osawa T
      – PersonEntity:
          Name:
            NameFull: Angel M
      – PersonEntity:
          Name:
            NameFull: Gupta S
      – PersonEntity:
          Name:
            NameFull: Khan O
      – PersonEntity:
          Name:
            NameFull: Bergthold G
      – PersonEntity:
          Name:
            NameFull: Liu B
      – PersonEntity:
          Name:
            NameFull: Kalaitzidou M
      – PersonEntity:
          Name:
            NameFull: Huseni M
      – PersonEntity:
          Name:
            NameFull: Scheffold C
      – PersonEntity:
          Name:
            NameFull: Powles T
      – PersonEntity:
          Name:
            NameFull: Choueiri TK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 07
              Text: 2023 Jul 15
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 402
            – Type: issue
              Value: 10397
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1